122 related articles for article (PubMed ID: 36510999)
1. Hepatocyte paraffin-1, CD10, and CD34 immunostaining as a diagnostic aid in cytologic diagnosis of hepatic cancer.
Agarwal A; Handa U; Kundu R; Sachdev A; Kochhar S
J Cancer Res Ther; 2022 Dec; 18(Supplement):S434-S438. PubMed ID: 36510999
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology.
Saad RS; Luckasevic TM; Noga CM; Johnson DR; Silverman JF; Liu YL
Diagn Cytopathol; 2004 Jan; 30(1):1-6. PubMed ID: 14696137
[TBL] [Abstract][Full Text] [Related]
3. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.
Ahuja A; Gupta N; Kalra N; Srinivasan R; Chawla Y; Rajwanshi A
Cytopathology; 2008 Aug; 19(4):229-35. PubMed ID: 18070122
[TBL] [Abstract][Full Text] [Related]
4. The Role of Immunocytochemical Markers to Differentiate Primary from Secondary Neoplastic Hepatic Masses: A Diagnostic Challenge on Cytology.
Bhattacharya JB; Jain SL; Devi S
Turk Patoloji Derg; 2021; 37(3):196-202. PubMed ID: 34514559
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
Radwan NA; Ahmed NS
Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of CD10 immunohistochemical staining on cellblock in differentiating hepatocellular carcinoma from secondary malignancies of liver.
Singha J; Khan K; Chatterjee S
Indian J Pathol Microbiol; 2018; 61(4):510-515. PubMed ID: 30303139
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.
Lin F; Abdallah H; Meschter S
Diagn Cytopathol; 2004 Feb; 30(2):92-7. PubMed ID: 14755758
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the CD34 and CD10 immunostains using a two-color staining protocol in liver fine-needle aspiration biopsies.
Zimmerman RL; Logani S; Baloch Z
Diagn Cytopathol; 2005 Feb; 32(2):88-91. PubMed ID: 15637673
[TBL] [Abstract][Full Text] [Related]
10. Two-color immunostaining of liver fine needle aspiration biopsies with CD34 and carcinoembryonic antigen. Potential utilization in the diagnosis of primary hepatocellular carcinoma vs. metastatic tumor.
Yoder M; Zimmerman RL; Bibbo M
Anal Quant Cytol Histol; 2004 Apr; 26(2):61-4. PubMed ID: 15131892
[TBL] [Abstract][Full Text] [Related]
11. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
12. The strength of cytomorphology and efficacy of immuno-cytochemistry in distinguishing hepatocellular carcinoma from its mimics on fine-needle aspiration cytology.
Chikhale M; Toi PC; Siddaraju N; Ananthakrishnan R
Diagn Cytopathol; 2021 Jul; 49(7):864-875. PubMed ID: 33929782
[TBL] [Abstract][Full Text] [Related]
13. Use of CD34 and factor VIII to diagnose hepatocellular carcinoma on fine needle aspirates.
Gottschalk-Sabag S; Ron N; Glick T
Acta Cytol; 1998; 42(3):691-6. PubMed ID: 9622689
[TBL] [Abstract][Full Text] [Related]
14. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens.
Timek DT; Shi J; Liu H; Lin F
Am J Clin Pathol; 2012 Aug; 138(2):203-10. PubMed ID: 22904131
[TBL] [Abstract][Full Text] [Related]
15. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.
Wang L; Vuolo M; Suhrland MJ; Schlesinger K
Acta Cytol; 2006; 50(3):257-62. PubMed ID: 16780018
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
Chu PG; Ishizawa S; Wu E; Weiss LM
Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
[TBL] [Abstract][Full Text] [Related]
17. The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma.
Karabork A; Kaygusuz G; Ekinci C
Pathol Res Pract; 2010 Aug; 206(8):572-7. PubMed ID: 20400233
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte paraffin 1 and arginase-1 are effective panel of markers in HBV-related HCC diagnosis in fine-needle aspiration specimens.
Moudi B; Mahmoudzadeh-Sagheb H; Heidari Z
BMC Res Notes; 2020 Aug; 13(1):388. PubMed ID: 32854754
[TBL] [Abstract][Full Text] [Related]
20. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
